Division of Infectious Diseases & HIV Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA.
Mount Sinai National Jewish Health Respiratory Institute, 10 East 102nd Street, New York City, NY 10029, USA.
Infect Dis Clin North Am. 2020 Dec;34(4):863-886. doi: 10.1016/j.idc.2020.06.001. Epub 2020 Sep 30.
Multidrug-resistant Mycobacterium tuberculosis remains a major public health threat; its management poses a significant economic burden. Treatment requires a programmatic approach with access to laboratory services, second-line medications, and adequate clinical resources. In recent years, we have seen rapid developments in diagnostic techniques with whole genome sequencing-based drug susceptibility prediction now in reach, an array of new drugs that transform treatment regimens to purely oral formulations, and a steady stream of multinational trials that inform us about most efficient combinations. Our hope is that the current momentum keeps the ambitious goal to end tuberculosis in 2030 in reach.
耐多药结核分枝杆菌仍然是一个主要的公共卫生威胁；其管理带来了巨大的经济负担。治疗需要一种方案方法，包括实验室服务、二线药物和充足的临床资源。近年来，我们看到诊断技术的快速发展，基于全基因组测序的药物敏感性预测现在已经成为可能，一系列新的药物将治疗方案转变为纯口服制剂，以及源源不断的跨国试验为我们提供了最有效的组合信息。我们希望当前的势头能够实现到 2030 年终结结核病的宏伟目标。
